EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Extracellular vesicles for Alzheimer’s disease therapy: mechanisms, engineering strategies, and clinical translation

Ailin Wu, Yan Zeng, Yilin Huang, Legao Chen, Shunyuan Guo, Jianwei Wang, Xiaozhou Mou, Xiaoru Chang

Extracellular Vesicles and Circulating Nucleic Acids · 28.07.2026 · 7 (3) · 1158-88

DOI: 10.20517/evcna.2026.43 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Extracellular Vesicles and Circulating Nucleic Acids, online erschienen am 28.07.2026. Verfasst von Ailin Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Zhejiang University of Technology, Hangzhou 310014, Zhejiang, China. Die Arbeit nennt 184 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD), a progressive neurodegenerative disorder, remains a major global health challenge owing to its complex pathogenesis and the presence of the blood-brain barrier (BBB), which substantially limits the delivery of effective therapeutics to the brain. Extracellular vesicles (EVs), which exhibit favorable biocompatibility, low immunogenicity, and an intrinsic capacity to cross the BBB, have emerged as promising therapeutic agents and delivery platforms for AD. This review focuses on the therapeutic potential of EV-based interventions in AD and summarizes recent advances in EV-mediated modulation of AD-related pathological processes, including amyloid-β (Aβ) clearance, tau protein regulation, neuroinflammation suppression, oxidative stress attenuation, and synaptic repair. Although EV-based therapies offer notable advantages, such as targeted BBB penetration and reduced immunogenic responses, their clinical translation remains constrained by safety concerns, including off-target effects, dose-dependent toxicity, and potential disturbances in neuroplasticity. In addition, this review discusses EV engineering strategies aimed at regulating the gut-brain axis (GBA), enhancing brain targeting, and advancing clinical translation. EV-based therapeutic interventions should therefore be developed within a safety-oriented framework supported by rigorous short- and long-term toxicological evaluation. Overall, this review highlights the therapeutic promise of EVs for AD while underscoring the need for rational engineering, standardized characterization, and safety-centered translational strategies to ensure clinical feasibility.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseMISEV2023clinical translationengineeringextracellular vesiclesgut-brain axisintranasal delivery

Autor:innen und Institutionen

  • College of Pharmacy, Zhejiang University of Technology, Hangzhou 310014, Zhejiang, China.
  • Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.
  • Translational Medicine Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.
  • General Surgery, Cancer Center, Department of Vascular Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.

Zitieren

APA

Wu, A., Zeng, Y., Huang, Y., Chen, L., Guo, S., Wang, J., Mou, X., & Chang, X. (2026). Extracellular vesicles for Alzheimer’s disease therapy: mechanisms, engineering strategies, and clinical translation. Extracellular Vesicles and Circulating Nucleic Acids, 7(3), 1158-88. https://doi.org/10.20517/evcna.2026.43

Vancouver

Wu A, Zeng Y, Huang Y, Chen L, Guo S, Wang J, et al. Extracellular vesicles for Alzheimer’s disease therapy: mechanisms, engineering strategies, and clinical translation. Extracellular Vesicles and Circulating Nucleic Acids. 2026;7(3):1158-88. doi:10.20517/evcna.2026.43

BibTeX
@article{Wu2026,
  author = {Wu, Ailin and Zeng, Yan and Huang, Yilin and Chen, Legao and Guo, Shunyuan and Wang, Jianwei and Mou, Xiaozhou and Chang, Xiaoru},
  title = {Extracellular vesicles for Alzheimer’s disease therapy: mechanisms, engineering strategies, and clinical translation},
  journal = {Extracellular Vesicles and Circulating Nucleic Acids},
  year = {2026},
  volume = {7},
  number = {3},
  pages = {1158--88},
  doi = {10.20517/evcna.2026.43}
}
Kostenlos starten →